3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Other solid neoplasm
1
Conditions
Melanoma
4
Carcinoma, Renal Cell
4
Carcinoma, Non-Small-Cell Lung
4
Carcinoma, Hepatocellular
3
Various Advanced Cancer
2
Stomach Neoplasms
2
Esophageal Neoplasms
2
Colorectal Neoplasms
2
Uterine Neoplasms
1
Uterine Cervical Neoplasms
1
Urothelial Cancer
1
Urinary Bladder Neoplasms
1
Thyroid Neoplasms
1
Rectal Neoplasms
1
Prostatic Neoplasms
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Neoplasms
1
Multiple Myeloma
1
Microsatellite Unstable Colorectal Cancer
1
Mesothelioma
1
Lymphoma
1
Lung Neoplasms
1
Hodgkin Disease
1
Hematologic Neoplasms
1
Glioma
1
Endometrial Neoplasms
1
Colonic Neoplasms
1
Breast Neoplasms
1
Advanced or Metastatic Solid Tumors
1
Interventions
pembrolizumab
2
Pemetrexed
2
Cisplatin
2
Nivolumab
1
Ipilimumab
1
Carboplatin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has announcements
×
Mesothelioma
×
Nivolumab
×
Clear all
NCT02899299
2024-05-21
CheckMate743
Bristol-Myers Squibb
Phase 3
Completed
605 enrolled
17 charts
1 FDA